The Afterparty Crash | SoftBank’s $5.8B Exit | Traders Smell Blood in the Silicon

The screens are calm… but it feels like the silence before a storm. Yesterday was the sugar high, today’s the comedown. 

Now, traders are blinking into the afterglow, unsure if they just saw a rebound or a mirage.

The Dow’s 400-point surge has stalled, futures are flat, and the same AI names that powered the rally are bleeding again.

CoreWeave plunged nearly 10% premarket after warning of data center delays, taking the air out of the AI trade that lifted markets barely 24 hours ago. 

Nvidia slipped as well, weighed down by SoftBank’s $5.8 billion exit, a sale that looks less like profit-taking and more like reallocation toward OpenAI’s endless burn. 

The broader tape isn’t crashing… it’s pausing. But the pause feels loaded. 

Investors are digesting a government “reopening” that funds Washington only until January, a healthcare sector repriced by lost subsidies, and an AI complex suddenly realizing that demand doesn’t equal capacity.

Monday’s rally was built on relief. Tuesday’s open smells like reality.

Data is still missing, Fed uncertainty still looms, and even Buffett’s letter can’t paper over a market learning the oldest rule in finance: relief rallies are the loudest before the next question hits.

Investor Signal

The market’s adrenaline rush is fading into reflection. 

Today’s mood is math. AI, healthcare, and rate bets all look stretched, and liquidity is thinning as politics hijack fundamentals.

Stay alert… the next move won’t come from earnings or guidance, but from whatever headline shatters this fragile calm.

President Trump just signed a new law…

That could unlock $21 trillion for everyday folks like you…

And potentially impact every checking and savings account in America.

Click here now because Chase, Bank of America, Citigroup, Wells Fargo, and U.S. Bancorp…

Are already preparing for what could be the biggest change to our financial system in 54 years.

The numbers finally leaked… and they read like a manifesto in code and cash.

Anthropic is quietly sprinting toward profit while OpenAI keeps torching billions to chase empire. Two roads, one AI boom: restraint versus mania.

Inside the spreadsheets, the contrast is brutal. 

Anthropic expects to break even by 2028, burning roughly $3 billion this year on $4.2 billion in sales. OpenAI, meanwhile, plans to lose $9 billion on $13 billion in revenue… and then double down, projecting $74 billion in losses by 2028. 

That’s not a typo. 

Sam Altman is betting on scale, building a trillion-dollar compute pipeline that turns every investor dollar into silicon, not profit. 

His plan reads less like a business model, more like a declaration of war: own the infrastructure, outspend everyone, and let history decide if it was vision or vanity.

Dario Amodei’s Anthropic is the anti-Altman: lean, enterprise-focused, allergic to hype. Eighty percent of its revenue comes from business clients, not viral demos. 

It skipped the video generators, skipped the humanoid dreams, and went where the margins live: code, compliance, and quiet contracts.

Deeper Read

The divergence isn’t just financial, it’s also philosophical. OpenAI is building mythology; Anthropic is building a business. 

One runs on charisma and compute; the other runs on recurring revenue. 

Investors now face a choice between two religions of AI: burn rate or balance sheet.

Investor Signal

Anthropic’s discipline gives it valuation durability, but OpenAI’s scale keeps it culturally untouchable… for now. 

If capital tightens or AI demand flattens, Anthropic becomes the benchmark for sustainability while OpenAI becomes a case study in overreach. 

Watch the cash flow curves: they’ll decide which company defines the next decade, and which one funds it.

Masayoshi Son just sold the crown jewel of the last AI boom to bankroll the next one.

SoftBank has unloaded its entire $5.83 billion stake in Nvidia —32 million shares gone in one October swing — as it reloads for what insiders are calling its most aggressive investment sprint since the Vision Fund’s birth.

The timing is audacious. 

Nvidia is still the world’s most valuable semiconductor company, yet Son walked away to free up capital for his new obsessions: OpenAI, Ampere, and the $500 billion Stargate project, a planetary-scale AI infrastructure play built squarely atop Nvidia chips. 

The paradox? He’s cashing out of the maker to fund the users.

This isn’t bearishness, it’s leverage. 

SoftBank is liquidating liquid gold to pile into the higher-multiple frontier of AI models and data centers. 

Analysts estimate Son needs at least $30 billion this quarter alone, including $22.5 billion for OpenAI. That’s more capital in three months than in the past two years combined.

Deeper Read

SoftBank’s Nvidia sale is a symbolic pivot from hardware profits to AI religion. Son no longer wants exposure to the tools, he wants to own the gods that wield them. 

But it’s also a high-wire act: a market jittery over AI valuations could turn his conviction into overreach. 

Vision Fund profits ballooned $19 billion this quarter, yet the share price wobbles, hinting investors aren’t sure whether to call this brilliance or brinkmanship.

Investor Signal

SoftBank’s exit marks a shift from chip-led certainty to model-driven risk. It’s betting the next trillion in AI wealth will come from cognition, instead of computation. 

But if OpenAI or Stargate stumble, Son won’t just miss the next wave, he’ll have sold the surfboard to buy the tide.

Remember when Bitcoin ETFs were just a rumor — then $37 billion poured in and prices exploded?

Now it’s altcoins’ turn. Over 90 ETF applications are pending with the SEC, and analysts expect approvals for Solana, XRP, and Litecoin soon.

The biggest gains come before ETFs launch, not after — smart money is already positioning.

That’s why we created the “Crypto Bull Run Millionaire Blueprint” — showing how to find undervalued altcoins and profit from the next wave.

[Get your copy before approvals hit →]

© 2025 Boardwalk Flock LLC. All Rights Reserved. 2382 Camino Vida Roble, Suite I Carlsbad, CA 92011, United States. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies. Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.

The diet-drug boom just went from luxury to policy.

After months of tariff threats and political posturing, Eli Lilly and Novo Nordisk walked into the Oval Office and walked out with something Wall Street didn’t expect:

Medicare coverage for obesity drugs. Prices drop, yes. But in exchange, the addressable market just exploded.

The math is ruthless but brilliant. 

Wegovy and Zepbound will soon cost around $245 a month under Medicare, down from four figures, with seniors paying a $50 copay. 

That’s a headline “cut” that hides a power move: Novo and Lilly are trading profit per prescription for tens of millions of new patients. Analysts peg the expansion at $27 billion in new annual sales, a scale-up no rival can easily match.

For Washington, it’s a PR win. 

For pharma, it’s a moat. 

By setting a new price floor, Lilly and Novo have slammed the door on smaller entrants like Pfizer and Roche, who now face the impossible task of competing in a mass market with luxury-level manufacturing costs. 

The GLP-1 wars have officially gone from exclusivity to ubiquity.

Deeper Read

Lilly and Novo knew price compression was coming, so they embraced it early, turning regulation into distribution. 

Oral versions of both drugs hit the FDA’s fast track next year, and with Trump’s “priority review” vouchers in hand, they’ll own the pill shelf before rivals clear trials. 

The deal also kneecaps compounders like Hims & Hers, whose gray-market semaglutide is suddenly less of a bargain.

Investor Signal

Lilly and Novo just reinvented Big Pharma’s growth model: volume as the new pricing power.

Margins narrow, but revenue durability skyrockets as obesity care becomes a Medicare staple. The next wave of returns will come from scale because the GLP-1 trade is institutionalizing.

Michael Burry just threw another grenade into Silicon Valley’s server rooms.

The man who shorted the housing bubble is now calling out the AI bubble’s balance sheet, accusing tech giants of using depreciation trickery to pad profits and mask how fast their shiny Nvidia-powered empires are aging.

In a post on X, Burry claimed companies like Meta, Oracle, Amazon, Microsoft, and Alphabet are committing “one of the great frauds of the modern era” by stretching the lifespan of their chips and servers to five or six years when the AI hardware cycle flips every two or three. 

In his math, that simple accounting tweak inflates earnings by $176 billion between 2026 and 2028, with Oracle overstating by 27% and Meta by 21%.

It’s classic Burry: not attacking innovation, but the illusion of it. 

Investors, he argues, are cheering paper profits built on equipment that depreciates faster than accountants admit. 

The irony? Even as he calls out “old chips,” they’re still moving. 

CoreWeave’s CEO said demand for older Nvidia models like the A100 and H100 remains strong, proof that the hardware “fraud” Burry warns of might be grayer than black-and-white.

Deeper Read

This isn’t just a valuation gripe, it’s a philosophy clash. The market is pricing eternity into tools built for obsolescence. 

AI’s top players are spending hundreds of billions on capex while amortizing those costs like factories, not fads. 

If Burry’s right, Wall Street’s favorite growth engines are running on borrowed time… and borrowed earnings.

Investor Signal

The AI trade is maturing faster than its spreadsheets admit. 

Capex is now the new cash flow, and depreciation has become a battleground. 

Whether Burry’s warning proves prophetic or premature, one truth cuts through the noise: in an industry sprinting at GPU speed, nothing ages faster than yesterday’s earnings.

Alex is one of a small circle of people to use this tiny company's groundbreaking AI technology...

And he believes in it so strongly, he scooped up thousands of shares.

You'll want to know what it is.

Details here…

CoreWeave did everything right… except keep the cranes on schedule.

The AI infrastructure darling blew past revenue expectations ($1.36B vs. $1.29B) and halved its expected loss per share. Yet the stock cratered 9% in premarket after executives admitted a partner’s data-center build hit delays. 

In the AI arms race, even a hiccup in “pouring concrete” now moves billions.

The company’s message was simple: demand isn’t the problem… capacity is. CEO Michael Intrator told investors that AI workloads “far exceed available supply,” but the 2025 revenue outlook ($5.05–$5.15B) came in just shy of Wall Street’s $5.29B dream. 

That’s all it took for traders to punish one of the sector’s most hyped post-IPO names.

Analysts still see strength. 

Melius Research kept a Buy rating but trimmed its target to $140 from $165, warning that CoreWeave might need to vertically integrate (build more of its own infrastructure) to avoid being handcuffed by third-party delays. 

Intrator said the worst of the slowdown should pass by early next year, with “even higher AI demand” waiting on the other side.

Deeper Read: Wall Street Wanted a Miracle, Got a Supply Chain

The irony is thick: CoreWeave’s biggest risk isn’t competition, it’s construction. 

Every bottleneck, from transformers to power shells, reminds investors that the physical world still throttles digital ambition. 

The canceled merger with Core Scientific only amplifies the story: CoreWeave is growing too fast for its own ecosystem.

Investor Signal

CoreWeave is still an AI arms dealer… just one caught waiting for the battlefield to finish being built. 

Revenue strength shows the hunger is real, but supply limits and missed timelines prove scaling AI is concrete — not code. 

The next rally depends less on GPUs and more on whether CoreWeave can pour faster than it promises.

The market’s running on caffeine and denial. 

Yesterday’s 400-point sprint looked like conviction; this morning, it looks like a reflex. Futures are flat, AI is wobbling, and the overnight calm feels staged… like traders holding their breath between storms.

Underneath the quiet, pressure is building. 

SoftBank’s $5.8B Nvidia sale stripped confidence from the chip trade, CoreWeave’s delay reminded everyone that AI still needs shovels and power lines, and the Fed’s December cut debate is turning into a coin toss. 

Washington may be “open” again, but policy clarity isn’t, and every missing data release leaves markets trading blind.

The mood? Hesitant optimism with a side of déjà vu. 

Monday’s relief rally was about escaping chaos; today’s tone is about calculating risk. Traders aren’t chasing momentum, they’re testing it.

The session ahead will hinge on whether the market can convert relief into resilience. If it can’t, yesterday’s comeback becomes tomorrow’s correction.

Morning takeaway: the headlines have cooled, but the floor’s still warm.